A consortium of investors led a $157m Series C round in Beijing Health Guard Biotechnology.

A consortium of investors including CCB International, Yunfeng Fund, Jimin Trust, Fuhai, Gaoshang Capital, Hongyin Capital and Yingke Capital led a $157m series C round in Beijing Health Guard Biotechnology, a biotechnology company. Funds raised in this round will be used for recombinant human papillomavirus trivalent vaccine, recombinant human papillomavirus nine valent vaccine clinical research costs, Kunming vaccine industry base construction costs, preclinical and clinical research costs of recombinant norovirus vaccines and recombinant new coronavirus vaccines, and preclinical research costs of other products under development and supplementary working capital.